Drugs / E3112
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03014895 | Jan → Jun 2017 | — | EA Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03922633 | Apr 2019 → May 2020 | — | EA Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E3112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03922633 ↗ |
| Route | Intravenous | “Intravenous E3112 infusion” NCT03014895 ↗ |